Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Poxviridae Infections Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Poxviridae Infections Overview | 10 | 1 |
| Pipeline Products for Poxviridae Infections Comparative Analysis | 11 | 1 |
| Poxviridae Infections Therapeutics under Development by Companies | 12 | 2 |
| Poxviridae Infections Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Poxviridae Infections Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Poxviridae Infections Products under Development by Companies | 17 | 1 |
| Poxviridae Infections Products under Investigation by Universities/Institutes | 18 | 1 |
| Poxviridae Infections Companies Involved in Therapeutics Development | 19 | 12 |
| Bavarian Nordic A/S | 19 | 1 |
| BioFactura, Inc. | 20 | 1 |
| CEL-SCI Corporation | 21 | 1 |
| Chimerix, Inc. | 22 | 1 |
| China Biologic Products, Inc. | 23 | 1 |
| CJ HealthCare Corp. | 24 | 1 |
| EpiVax, Inc. | 25 | 1 |
| N &N Pharmaceuticals Inc. | 26 | 1 |
| SIGA Technologies, Inc. | 27 | 1 |
| Takeda Pharmaceutical Company Limited | 28 | 1 |
| Tonix Pharmaceuticals Holding Corp. | 29 | 1 |
| Verrica Pharmaceuticals Inc. | 30 | 1 |
| Poxviridae Infections Therapeutics Assessment | 31 | 10 |
| Assessment by Monotherapy Products | 31 | 1 |
| Assessment by Combination Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 2 |
| Assessment by Route of Administration | 37 | 2 |
| Assessment by Molecule Type | 39 | 2 |
| Drug Profiles | 41 | 42 |
| (plague + small pox) vaccine Drug Profile | 41 | 1 |
| 24a Drug Profile | 42 | 1 |
| BA-368 Drug Profile | 43 | 1 |
| brincidofovir Drug Profile | 44 | 13 |
| CEL-1000 Drug Profile | 57 | 2 |
| CJ-40011 Drug Profile | 59 | 1 |
| imatinib mesylate Drug Profile | 60 | 1 |
| Monoclonal Antibodies for Infectious Disease Drug Profile | 61 | 1 |
| Monoclonal Antibody for Smallpox Drug Profile | 62 | 1 |
| nilotinib Drug Profile | 63 | 1 |
| NN-001 Drug Profile | 64 | 1 |
| PL-801 Drug Profile | 65 | 1 |
| SCV-305 Drug Profile | 66 | 1 |
| Small Molecules for Molluscum Contagiosum Drug Profile | 67 | 1 |
| small pox vaccine Drug Profile | 68 | 1 |
| smallpox vaccine Drug Profile | 69 | 4 |
| smallpox vaccine Drug Profile | 73 | 1 |
| tecovirimat Drug Profile | 74 | 5 |
| varicella hyperimmune globulins Drug Profile | 79 | 1 |
| VIR-001 Drug Profile | 80 | 1 |
| VIR-002 Drug Profile | 81 | 1 |
| VP-100 Drug Profile | 82 | 1 |
| Poxviridae Infections Dormant Projects | 83 | 3 |
| Poxviridae Infections Discontinued Products | 86 | 1 |
| Poxviridae Infections Product Development Milestones | 87 | 8 |
| Featured News &Press Releases | 87 | 1 |
| Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government | 87 | 1 |
| Apr 25, 2016: SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat | 87 | 1 |
| Mar 17, 2016: SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX | 87 | 1 |
| Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA s Tecovirimat Antiviral | 88 | 1 |
| Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA s Tecovirimat Antiviral | 88 | 1 |
| Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox | 88 | 1 |
| Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene | 89 | 1 |
| Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox | 89 | 1 |
| Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox | 90 | 1 |
| Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million | 90 | 1 |
| May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine | 91 | 1 |
| Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery | 92 | 1 |
| Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess ... | 92 | 1 |
| Dec 23, 2014: Chimerix Provides Recap of 2014 Events | 93 | 1 |
| Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine | 94 | 1 |
| Appendix | 95 | 2 |
| Methodology | 95 | 1 |
| Coverage | 95 | 1 |
| Secondary Research | 95 | 1 |
| Primary Research | 95 | 1 |
| Expert Panel Validation | 95 | 1 |
| Contact Us | 95 | 1 |
| Disclaimer | 96 | 1 |
